http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-1260463-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_97a285d8ecd0184a7e5d89a1e4e07997 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-096 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D333-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-096 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate | 1984-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1989-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c35d9a0095f4b083c0fa324a6596e02d |
| publicationDate | 1989-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-1260463-A |
| titleOfInvention | 2,5-disubstituted-4(3h)-pyrimidones having histamine h.sub.2-receptor antagonist activity |
| abstract | Abstract Of The Disclosure Histamine H2-antagonists of the formula: wherein m is an integer of from zero to 2, inclusive; n is an integer of from 2 to 5 inclusive: z is sulfur, oxygen or methylene; R1 is NO2 or NR2R3; R2 and R3 each are independently hydrogen or (lower)alkyl, or, when R2 is hydrogen, R3 also may be formyl, carboalkoxy, alkanoyl or benzoyl; A is phenyl, furyl, thienyl, pyridyl, thiazolyl, imidazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, tria-zolyl, isoxazolyl, isothiazolyl, pyrimidinyl,pyrazolyl, pyridazinyl or pyrazinyl; provided that A contains one or two substituents, the first substituent being selected from and the second substituent being selected from (lower)-alkyl, hydroxy, trifluoromethyl, halogen, amino, hydroxy-methyl and (lower)alkoxy; q is an integer of from 0 to 6, inclusive; R4 is a hydrogen atom, a (lower)alkyl group optionally substituted by one or more halogen atoms, provided that there is no halogen atom on the carbon atom attached to the nitrogen atom, or a cyclo(lower)alkyl, cyclo(lower)alkyl(lower)-alkyl, (lower)alkanoyl or benzoyl group; R6 and R7 each are independently hydrogen, (lower)alkyl, (lower)alkenyl, (lower)alkynyl, phenyl-(lower)alkyl or (lower)alkoxy(lower)alkyl in which the (lower)alkoxy moiety is at least two carbon atoms removed from the nitrogen atom, or R6 and R7, taken together with the nitrogen atom to which they are attached, may be pyrrolidino, methylpyrrolidino, dimethylpyrrolidino, morpholino, thiomorpholino, piperidino, methylpiperidino, dimethylpiperidino, hydroxypiperidino, N-methylpipera-zino, homopiperidino, heptamethyleneimino, octamethylene-imino or 3-azabicyclo[3.2.2]non-3-yl; or a nontoxic pharmaceutically acceptable acid addition salt thereof. -b- |
| priorityDate | 1983-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 172.